Lv1
56 积分 2025-11-02 加入
Lecanemab real-world treatment outcomes from cohort study in early Alzheimer's disease
23天前
已关闭
Aging modulates amyloid clearance kinetics during anti-amyloid therapy: evidence from real-world serial amyloid PET
26天前
已完结
Dynamic changes in plasma biomarkers of Alzheimer's disease in patients treated with lecanemab: a longitudinal cohort study
26天前
已完结
Lower baseline cerebrospinal fluid amyloid-β 42 is associated with amyloid-related imaging abnormalities during real-world lecanemab treatment
26天前
已完结
Real‐world implementation of lecanemab in Alzheimer's disease: A Japanese cohort
26天前
已完结
Real‐world evidence for amyloid‐targeted therapies: Lecanemab and donanemab
26天前
已完结
Demographic and Clinical Characteristics of Patients Treated With Lecanemab Stratified by Amyloid-Related Imaging Abnormality Status
27天前
已完结
Real‐world implementation of lecanemab in Korean patients at a tertiary memory clinic: Safety, ARIA risk, and early treatment patterns
2个月前
已完结
Temporal Evolution of ARIA After Lecanemab Interruption: A Longitudinal Volumetric MRI Study
4个月前
已完结
Real-World Experience with Lecanemab for Alzheimer's Disease
5个月前
已关闭
皖公网安备34019202002308
